Last 43 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.59 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | 73.27 | — | — | — | 19.90 | 441.10 | 2440.10 | 31.79 | 54.39 | 987.46 | 37.29 | 49.94 | 75.47 | 70.75 | 58.36 | 43.65 | 31.09 | 74.31 |
| — | — | — | +268.2% | — | — | — | -63.4% | -55.3% | +6443.4% | -36.3% | -27.9% | +1295.6% | -36.1% | +14.4% | +142.7% | -4.8% | -47.5% | -38.7% | -51.8% | +236.0% | |
| P/B Ratio | 1.13 | 1.60 | 1.72 | 1.20 | 1.49 | 1.27 | 1.00 | 0.97 | 0.87 | — | — | 8.14 | 4.45 | 3.95 | 4.87 | 7.93 | 9.97 | 11.88 | 11.93 | 37.22 | — |
| — | +25.9% | +71.3% | +23.7% | +71.8% | — | — | -88.1% | -80.5% | — | — | +2.6% | -55.3% | -66.8% | -59.2% | -78.7% | — | -96.9% | -83.4% | -83.0% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 5.29 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.07 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 50.0% | — | — | — | 96.3% | -575.0% | -44100.0% | 56.1% | 100.0% | -23200.0% | 66.0% | 72.9% | 60.7% | -351.9% | 80.0% | 83.9% | -93.5% | 39.0% |
| — | — | — | -48.1% | — | — | — | -3.7% | +97.5% | -66918.2% | -23.0% | +64.6% | -6492.9% | -17.5% | -13.1% | +165.0% | -1001.9% | -3.4% | -3.8% | -270.5% | -51.3% | |
| Operating Margin | — | — | — | -6660.0% | — | — | — | -2384.0% | -51525.0% | -158800.0% | -1731.6% | -5119.6% | -66075.0% | -1628.0% | -1322.4% | -1843.7% | -722.7% | -522.5% | -385.9% | 561.2% | -417.3% |
| — | — | — | -179.4% | — | — | — | +53.4% | +22.0% | -9654.3% | -30.9% | -177.7% | -9042.5% | -211.6% | -242.7% | -428.5% | -73.2% | -57.9% | -22.0% | +280.0% | -1.8% | |
| Net Margin | — | — | — | -7900.0% | — | — | — | -2432.1% | -8450.0% | -158600.0% | -1686.7% | -5031.4% | -65950.0% | -1654.7% | -1323.4% | -1881.5% | -725.4% | -377.5% | -387.2% | -291.9% | -440.4% |
| — | — | — | -224.8% | — | — | — | +51.7% | +87.2% | -9485.0% | -27.5% | -167.4% | -8991.8% | -338.3% | -241.8% | -544.6% | -64.7% | -7.8% | +7.4% | +9.9% | -48.8% |
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -103.6% | -29.5% | -26.1% | -27.9% | -21.1% | -41.5% | -16.7% | -26.7% | -9.5% | — | -314.6% | -104.5% | -57.2% | -36.6% | -39.0% | -40.2% | -23.6% | -17.9% | -39.1% | -234.2% | -1487.8% |
| — | +28.9% | -56.6% | -4.5% | -121.8% | — | +94.7% | +74.5% | +83.4% | — | -705.9% | -159.8% | -142.8% | -104.2% | +0.2% | +82.8% | +98.4% | +86.8% | +76.5% | +14.9% | — | |
| ROA | -85.5% | -26.5% | -22.2% | -24.2% | -19.2% | -38.1% | -14.4% | -21.8% | -6.3% | -106.4% | -53.1% | -49.7% | -36.1% | -26.6% | -27.8% | -28.8% | -18.1% | -13.3% | -24.1% | -38.3% | -55.5% |
| — | +30.5% | -54.1% | -11.1% | -206.9% | +64.2% | +72.9% | +56.1% | +82.7% | -299.6% | -91.3% | -72.4% | -99.6% | -100.8% | -15.1% | +24.8% | +67.3% | +67.1% | +50.8% | +27.9% | -19.4% | |
| ROIC | -12206.3% | — | — | — | — | — | -390.8% | -267.9% | — | — | — | — | — | — | — | — | — | — | — | — | -413.6% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -76.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 0.01 | 0.09 | 0.07 | — | — | 0.14 | 0.06 | 0.04 | 0.03 | 0.06 | 0.04 | 0.04 | 0.07 | 0.23 | — |
| — | — | — | — | — | — | — | -38.0% | +20.6% | — | — | +135.8% | +40.3% | +7.4% | -53.2% | -74.6% | — | -98.8% | -91.9% | -92.6% | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.13 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.05 | 11.60 | 7.73 | 6.05 | 9.71 | 12.22 | 11.83 | 5.55 | 5.30 | 0.27 | 0.73 | 1.37 | 2.19 | 3.06 | 4.23 | 2.71 | 4.59 | 4.22 | 3.51 | 1.74 | 1.13 |
| — | -5.1% | -34.7% | +9.0% | +83.0% | +4429.4% | +1521.3% | +305.3% | +142.8% | -91.2% | -82.7% | -49.4% | -52.4% | -27.7% | +20.4% | +56.1% | +306.1% | +136.1% | +27.5% | -24.8% | -0.2% | |
| Quick Ratio | 6.05 | 11.60 | 7.73 | 6.05 | 9.71 | 12.22 | 11.83 | 5.55 | 5.30 | 0.27 | 0.69 | 1.33 | 2.01 | 2.87 | 4.10 | 2.60 | 4.53 | 4.17 | 3.45 | 1.66 | 0.95 |
| — | -5.1% | -34.7% | +9.0% | +83.0% | +4429.4% | +1623.6% | +317.6% | +163.9% | -90.6% | -83.3% | -48.8% | -55.6% | -31.2% | +18.7% | +56.8% | +377.2% | +162.6% | +37.4% | -18.4% | +25.3% | |
| Interest Coverage | — | — | — | — | — | — | — | -58.52 | -187.36 | — | — | — | — | -488.40 | -2539.00 | -829.67 | — | — | -2632.00 | 116.31 | -19.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 43 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TTNP stock.
Titan Pharmaceuticals, Inc.'s current P/E is -0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Titan Pharmaceuticals, Inc.'s business trajectory between earnings reports.